Deerfield Management’s Larimar Therapeutics LRMR Stock Holding History

Deerfield Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$109M	Hold	35,606,974	–	–	1.13%	26
2026 Q1	$160M	Buy	35,606,974 +5,000,000	+16%	+$20M	1.89%	12
2025 Q4	$117M	Hold	30,606,974	–	–	1.49%	20
2025 Q3	$98.9M	Buy	30,606,974 +9,375,000	+44%	+$35.2M	1.51%	16
2025 Q2	$61.4M	Hold	21,231,974	–	–	1.11%	24
2025 Q1	$45.6M	Hold	21,231,974	–	–	0.9%	27
2024 Q4	$82.2M	Hold	21,231,974	–	–	1.56%	18
2024 Q3	$139M	Hold	21,231,974	–	–	2.08%	9
2024 Q2	$154M	Hold	21,231,974	–	–	2.56%	8
2024 Q1	$161M	Buy	21,231,974 +4,290,617	+25%	+$33.4M	2.8%	4
2023 Q4	$77.1M	Hold	16,941,357	–	–	1.42%	21
2023 Q3	$66.9M	Hold	16,941,357	–	–	1.47%	18
2023 Q2	$53M	Hold	16,941,357	–	–	1.13%	26
2023 Q1	$76.7M	Hold	16,941,357	–	–	1.71%	17
2022 Q4	$70M	Hold	16,941,357	–	–	1.45%	25
2022 Q3	$54.2M	Buy	16,941,357 +11,111,108	+191%	+$27.8M	1.08%	30
2022 Q2	$11.4M	Hold	5,830,249	–	–	0.24%	74
2022 Q1	$23.6M	Hold	5,830,249	–	–	0.53%	45
2021 Q4	$62.9M	Hold	5,830,249	–	–	1.32%	23
2021 Q3	$67.2M	Hold	5,830,249	–	–	1.31%	20
2021 Q2	$57.3M	Buy	5,830,249 +685,710	+13%	+$7.75M	1.02%	24
2021 Q1	$75.2M	Hold	5,144,539	–	–	1.58%	16
2020 Q4	$110M	Hold	5,144,539	–	–	2.18%	9
2020 Q3	$78M	Hold	5,144,539	–	–	1.9%	13
2020 Q2	$66.1M	Buy	+5,144,539	New	+$59.9M	1.93%	14
2016 Q3	–	Sell	-254,634	Closed	-$18.3M	–	98
2016 Q2	$18.3M	Hold	254,634	–	–	0.72%	48
2016 Q1	$20.4M	Buy	254,634 +184,329	+262%	+$14.6M	0.87%	41
2015 Q4	$5.31M	Buy	70,305 +24,182	+52%	+$3.88M	0.22%	79
2015 Q3	$17.7M	Sell	46,123 -37,845	-45%	-$17.1M	0.68%	53
2015 Q2	$34.9M	Sell	83,968 -3,547	-4%	-$1.48M	1.16%	27
2015 Q1	$41.6M	Buy	+87,515	New	+$41.5M	1.35%	18

Other funds holding LRMR

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Deerfield Management's LRMR Position: Q2 2026 in Review

Deerfield Management held its Larimar Therapeutics (LRMR) position steady in Q2 2026 at 35,606,974 shares worth $109M. The position accounts for 1.13% of the portfolio, ranked #26.

Deerfield Management first reported a position in LRMR in Q1 2015 and has held it in 31 quarters since. The position peaked at $161M in Q1 2024. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Deerfield Management held 35,606,974 shares of Larimar Therapeutics worth $109M as of Q2 2026.
Deerfield Management left its Larimar Therapeutics share count unchanged in Q2 2026.
Larimar Therapeutics made up 1.13% of Deerfield Management's portfolio in Q2 2026, its #26 holding.
Deerfield Management first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 31 quarters since.
Deerfield Management's Larimar Therapeutics position peaked at $161M in Q1 2024.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.